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Friend or Foe for
Cardiac Hypertrophy?MicroRNAs (miRNAs) play an important role in the
pathogenesis of structural alterations of cardiac hy-
pertrophy (1). However, the precise mechanisms of
miRNA-29a in cardiac hypertrophy are still unclear.
A recent report in the Journal by Roncarati et al. (2)
indicated that correlation with left ventricular hy-
pertrophy parameters holds true for only miRNA-
29a, which is signiﬁcantly associated with both
cardiac hypertrophy and ﬁbrosis. This suggests that
miRNA-29a is a potential therapeutic target for car-
diac hypertrophy.
Other studies have found that down-regulation of
miRNA-29a is associated with pathological cardiac
hypertrophy. Abonnenc et al. (3) showed that levels
of miRNA-29a were signiﬁcantly reduced in a mouse
model of pathological but not physiological hyper-
trophy (3). Furthermore, Divakaran et al. (4) indi-
cated that Smad3 signaling plays dual roles in the
heart: a beneﬁcial role by delimiting hypertrophic
growth and a deleterious role by modulating myo-
cardial ﬁbrosis, possibly through a pathway that en-
tails accumulation of miRNA-29a, which decreases
collagen gene expression. However, Zile et al. (5)
showed that miRNA-29a levels increased 5 days after
myocardial infarction and then decreased to control
levels at later time points. A time-dependent change
in miRNA-29a levels occurred in patients
with myocardial infarction, including an early and
robust increase in miRNA levels that affected myo-
cardial ﬁbrosis.
These ﬁndings suggest that miRNA-29a may be
a good clinical biomarker for patients with cardiac
hypertrophy because it seems to play a key role in
the development of this condition. Additional studieswith more patients and animal studies are needed
to determine the precise role of miRNA-29a in car-
diac hypertrophy, and therapeutic agents targeting
miRNA-29a might result in innovative new therapies.
All in all, we greatly enjoyed reading the article by
Roncarati et al. (2) and believe that miRNA-29a may
be useful for the prevention and treatment of cardiac
hypertrophy.Hui Tao, MD
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Interleukin Genotypes
Potentiate Early and
Advanced Atherosclerosis
DifferentlyWe read with interest the paper by Tsimikas et al.
(1) in a recent issue of the Journal, which reported
that genetic differences in the interleukin (IL)-1 gene
cluster, known to be associated with inﬂammatory
responsiveness, strongly inﬂuence the presence of
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(CAD) mediated by atherogenic oxidized phospho-
lipids and lipoprotein (Lp) (a). These ﬁndings suggest
that the atherogenic potential of pro-inﬂammatory
cytokines and lipids is conditional and determined
by a complex and synergistic interplay of environ-
mental and genetic risk factors.
Because of the various manifestations of CAD and
the multiple risk factors involved in the progression
of the disease (2), it is difﬁcult to fully determine the
underlying mechanisms of the pathophysiology of
CAD and especially the impact of the interleukin
family on mechanisms of atherosclerosis. In their
elegant study, Tsimikas et al. (1) not only documented
the interaction between IL-1 and atherogenic lipids
but also evaluated their effects independently from
a cluster of well-known atherosclerotic risk factors.
The network of mechanisms involved in athero-
sclerosis includes clinical factors (diabetes, smoking
habits, renal function, obesity), arterial wall proper-
ties, endothelial function, coagulation status, and a
complex interplay between inﬂammatory cataract
and lipids metabolism. However, IL-1 plays an im-
portant role in early atherosclerosis, whereas IL-6 is
a mediator of advanced atherosclerosis and predis-
poses to acute coronary syndromes. In this setting,
we examined the synergistic effect of IL-6 gene poly-
morphism (rs1800795) and smoking status on the
risk and severity of CAD. We found that genetic sus-
ceptibility to increase IL-6 levels in smokers was
associated with the incidence and severity of CAD
independently of other known risk factors, but there
was no such association in nonsmokers (3).
The ﬁndings of Tsimikas et al. (1) and our ﬁndings
(3) suggest the divergent role of interleukins in the
different phases of atherosclerosis. Both IL-1 and IL-6
are implicated in mechanisms of atherosclerosis.
IL-1 levels are elevated in atherosclerotic human
coronary arteries compared with normal arteries andcan predict future myocardial infarction (4). IL-6
levels stimulate hepatic production of acute phase
proteins such as C-reactive protein and ﬁbrinogen,
regulate extracellular matrix deposition and reorga-
nization, and have been identiﬁed not only as pre-
dictors of acute coronary syndromes but also as
biomarkers of adverse outcomes (5).
There is a complex and synergistic interplay
between genes encoding inﬂammatory cytokines,
lipid metabolism, and clinical risk factors that must
be elucidated in depth to further understand and
manage atherosclerosis and plaque instability.Evangelos Oikonomou, MD
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